Mobile

Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-002633-20

Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To investigate the MRI efficacy of six months' administration of Firategrast in subjects with relapsing-remitting MS

Critère d'inclusion

  • Relapsing-Remitting Multiple Sclerosis

Liens